Actress Yuri Nakamura, known across film and television projects in Japan and internationally, died on September 1 at the age of 44 following a battle with rectal cancer, according to an announcement from her agency, Alpha Agency. Nakamura, a fourth-generation Zainichi Korean whose Korean name is Sung Woo-ri, passed away surrounded by her family after a medical journey that spanned more than a decade.
Medical Timeline and Career Context
According to Alpha Agency, Nakamura was first diagnosed with cancer 13 years prior to her passing. Following initial treatments, she maintained her health through regular checkups. However, the cancer recurred in January of the previous year, requiring surgery. Subsequent tests revealed the disease had metastasized to other parts of her body, prompting ongoing medical management.
Nakamura had planned to return to her professional schedule in August, but the emergence of a sudden intestinal obstruction led to a terminal diagnosis. Her agency noted that she kept a calm and gentle smile through her final days, spending precious time with her close family members. She had been slated to star in the upcoming 2027 drama series Dangerous, but ultimately withdrew from the project as her health deteriorated.
From Idol to Screen Actor
Born in 1982 to a third-generation Zainichi Korean father and a South Korean mother, Nakamura entered the entertainment industry in 1996 through an audition program. She launched her career as a singer in 1998 as part of the idol group YuriMari before transitioning to acting.
As a film and television actor, Nakamura built a resume across multiple genres. Her cinematic credits include roles in Pacchigi! Love & Peace, Ju-on Black Girl, Miracles May Happen, Like Father, Like Son, and Ring: Cursed Photo. On television, she appeared in programs such as Tokyo Dogs, Good Doctor, We are Crazy, and 119 Emergency Call.
In 2025, she expanded her reach to global audiences by appearing alongside actress Han Hyo-joo in the Netflix series Romantic Anonymous.
Worth a look
- Wolverhampton 19:30 Racing Tips & Predictions
- Classroom of the Elite: Anime, Manga, and New B6 Novel Format
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)